Optigenex Inc.
Records under this name other than the patents Optigenex Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,595,064 | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals Term ended Term ended Aug 27, 2022 · From the USPTO record | Term ended | Term ended Aug 27, 2022 | From the USPTO record |
| US 6,964,784 | Method of Preparation and Composition of a Water Soluble Extract of the Bioactive Component of the Plant Species Uncaria for Enhancing Immune, Anti-Inflammatory, Anti-Tumor and DNA Repair Processes of Warm Blooded Animals Term ended Term ended Mar 7, 2022 · From the USPTO record | Term ended | Term ended Mar 7, 2022 | From the USPTO record |
| US 7,947,312 | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals Term ended Ended no later than Mar 7, 2022 · From the USPTO record | Term ended | Ended no later than Mar 7, 2022 | From the USPTO record |
| US 7,955,626 | Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester Term ended Term ended Mar 7, 2022 · From the USPTO record | Term ended | Term ended Mar 7, 2022 | From the USPTO record |
| US 8,372,448 | Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester Term ended Term ended Mar 7, 2022 · From the USPTO record | Term ended | Term ended Mar 7, 2022 | From the USPTO record |
| US 8,372,449 | Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering pruified quinic acid and/or carboxy alkyl ester Term ended Term ended Mar 7, 2022 · From the USPTO record | Term ended | Term ended Mar 7, 2022 | From the USPTO record |
| US 6,238,675 | Method of preparation and composition of a water soluble extract of the plant species Uncaria for enhancing immune, anti-inflammatory and anti-tumor processes of warm blooded animals Term ended Term ended Nov 16, 2019 · From the USPTO record | Term ended | Term ended Nov 16, 2019 | From the USPTO record |
| US 6,039,949 | Method of preparation and composition of a water soluble extract of the plant species uncaria Term ended Term ended Feb 27, 2017 · From the USPTO record | Term ended | Term ended Feb 27, 2017 | From the USPTO record |
| US 6,361,805 | Method of preparation and composition of a water soluble extract of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals Term ended Term ended Feb 27, 2017 · From the USPTO record | Term ended | Term ended Feb 27, 2017 | From the USPTO record |
| US 6,020,351 | Carotenoid-nicotinamide-zinc compositions and methods of treatment using same Lapsed on the fee record Ended Feb 1, 2008 · From the USPTO record | Lapsed on the fee record | Ended Feb 1, 2008 | From the USPTO record |